Change lives in myelofibrosis with JAKAVI1–3
JAKAVI (ruxolitinib) is the only licensed oral JAK1 and JAK2 inhibitor targeted therapy approved to treat adult patients with myelofibrosis (MF).1
JAKAVI (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.1
- Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
- Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
- Harrison C, et al. N Engl J Med. 2012;366:787–798.